Concord Biotech Board of Directors

Get the latest insights into the leadership at Concord Biotech. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Mr. Sudhir Vaid Chairman & Managing Director
Mr. Ankur Vaid Joint Managing Director & CEO
Mr. Ravi Kapoor Non Executive Director
Mr. Rajiv Ambrish Agarwal Non Executive Director
Mrs. Bharti Khanna Independent Director
Mr. Amitabh Thakore Independent Director
Mr. Arvind Agarwal Independent Director
Mr. Jayaram Easwaran Independent Director
Mr. Mandayam Chakravarthy Sriraman Independent Director

Concord Biotech Share price

CONCORDBIO

1714.7

19.00 (1.12%)
NSE
BSE
Last updated on 29 Aug, 2025 | 09:42 IST
BUYSELL
Today's High

1715.90

Today's Low

1687.00

52 Week Low

1345.00

52 Week High

2664.00

The current prices are delayed, login to your account for live prices

Concord Biotech FAQs

The board at Concord Biotech consists of experienced professionals, including Mr. Sudhir Vaid , Mr. Ankur Vaid , and others, overseeing the company’s strategic and corporate governance.

Directors at Concord Biotech are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Mr. Sudhir Vaid is the current chairman at Concord Biotech.

Executive directors at Concord Biotech are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Concord Biotech adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Concord Biotech, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.